GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No.

GRI Bio，Inc.（纳斯达克：GRI）（“GRI Bio”或“公司”）是一家生物技术公司，致力于开发用于治疗炎症，纤维化和自身免疫性疾病的自然杀伤T（NKT）细胞调节剂的创新管道，今天宣布，韩国知识产权局（KIPO）已发布第号专利申请的专利授予通知。

10-2017-7018579 titled, 'Prevention and Treatment of Inflammatory Conditions.'The issued patent covers claims including compositions and methods for modulating type 2 and/or type 1 invariant NKT (iNKT) cells in the prevention and treatment of inflammatory conditions of the liver. More specifically, when issued the patent will cover the prevention and treatment of inflammatory and fibrotic conditions through the administration of a Retinoic Acid Receptor (RAR) agonist that inhibits iNKT cells and the administration of an RAR agonist that inhibits the activity of iNKT cells in a subject.“We are pleased to add this Korea patent to our intellectual property portfolio covering our innovative pipeline of NKT cell modulators.

10-2017-7018579标题为“炎症的预防和治疗”已发布的专利涵盖了权利要求，包括用于在预防和治疗肝脏炎症状况中调节2型和/或1型不变NKT（iNKT）细胞的组合物和方法。更具体地说，当专利发布时，将涵盖通过施用抑制iNKT细胞的视黄酸受体（RAR）激动剂和施用抑制受试者中iNKT细胞活性的RAR激动剂来预防和治疗炎症和纤维化病症。“我们很高兴将这项韩国专利添加到我们的知识产权组合中，涵盖我们创新的NKT细胞调节剂管道。

Each granted patent provides further validation and bolsters our confidence of our differentiated approach to the prevention and treatment of inflammatory, fibrotic and autoimmune diseases. As we continue to advance our development programs forward, we remain steadfast in our commitment to expand our IP globally and position the Company to address the global unmet need amongst patients for much needed treatment options,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.GRI Bio is currently advancing its lead program GRI-0621, a small molecule RAR-βɣ dual agonist candidate that inhibits the activity of human iNKT cells, in a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-.

每个授予的专利都提供了进一步的验证，并增强了我们对预防和治疗炎症，纤维化和自身免疫性疾病的差异化方法的信心。随着我们继续推进我们的发展计划，我们仍然坚定地致力于在全球范围内扩大我们的知识产权，并使公司能够解决患者对急需治疗方案的全球未满足需求，”GRI Bio.GRI Bio首席执行官Marc Hertz博士目前正在推进其领先项目GRI-0621，这是一种小分子RAR-βɣ双重激动剂候选物，可抑制人类iNKT细胞的活性，处于2a期，随机，双盲，多中心，安慰剂对照，平行。